AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026?

AbbVie is a diversified pharmaceutical company that provides stable cash flows through its established drug portfolio. CRISPR Therapeutics AG is a clinical-stage biotechnology firm focused on the high-reward potential of gene therapy. These companies represent two ends of the healthcare spectrum, making them a fascinating pair for investors to compare.

The case for AbbVie

Many investors view the choice between these two as a classic biotech vs pharma comparison, where established stability meets high-stakes innovation. AbbVie focuses on discovering and commercializing medicines for complex health issues, with a strong emphasis on its immunology and aesthetics segments. The company distributes its products primarily through large wholesalers, including McKesson (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR). Customer concentration like this adds a layer of risk to the business, as these three distributors handle nearly all of its pharmaceutical products in the United States.

In FY 2025, revenue reached close to $61.2 billion, indicating growth of approximately 8.6% compared to the previous year. This revenue performance supported a net income of roughly $4.2 billion for the same period. While the net margin decreased slightly from previous years to 6.9%, the company maintains a massive global footprint with products serving patients in over 175 countries. The growth in newer products like Skyrizi and Rinvoq helps offset the impact of competition for older medications.

AbbVie carries a debt-to-equity ratio of -21.1x according to its December 2025 balance sheet. This figure means total liabilities exceed shareholder equity. The current ratio, which measures a company's ability to cover its short-term obligations with its current assets, is approximately 0.7x. Despite these balance sheet metrics, the company remains a cash-generating engine, producing free cash flow of nearly $17.8 billion in FY 2025. Free cash flow is the cash left over after a company pays for its operating activities and capital expenditures.

The case for CRISPR Therapeutics

CRISPR Therapeutics operates at the frontier of genomic medicine, developing therapies that aim to cure diseases by editing the human genome. The company is highly dependent on Vertex (NASDAQ:VERX) for the development and commercialization of its lead program, CASGEVY. Currently, the company does not generate revenue from the direct sale of its own products, instead receiving 40% of the net profits or losses from its collaborative programs. This business model relies heavily on the long-term success of its partners and the adoption of its novel technology.

In FY 2025, revenue reached nearly $3.5 million, which represents a 90% decline from the prior year when milestone payments were higher. The company reported a net loss of approximately $581.6 million for the fiscal year. This loss is characteristic of biotechnology firms that invest heavily in research and development before their products reach full commercial scale. Because the company is still in its growth phase, its income statement is often defined by these high levels of spending relative to current revenue.

As of its December 2025 balance sheet, the company maintains a very conservative capital structure with a debt-to-equity ratio of 0.2x. This ratio measures total debt against shareholder equity and suggests that the company is not heavily burdened by debt. The current ratio is an impressive 13.3x, indicating a strong ability to meet short-term financial needs. However, the company is still burning cash, with free cash flow for FY 2025 resulting in a loss of close to $345.9 million.

Risk profile comparison

AbbVie faces significant revenue concentration risks, as a large portion of its sales comes from just a few key immunology drugs. This leaves the company vulnerable to competitive pressures and the loss of patent protection. Additionally, government-mandated pricing controls under the Inflation Reduction Act impact the net revenue of several major products. Intense competition from biosimilars, particularly those targeting Humira, continues to be a primary concern for the business. Legal challenges and patent litigation regarding product exclusivity also create ongoing uncertainty for shareholders.

CRISPR Therapeutics faces risks related to its financial viability, as the company expects to incur significant losses for the foreseeable future. There is a high dependence on Vertex for the commercial success of its primary programs, and the company lacks control over many essential activities. The gene-editing technology itself is novel and largely unproven over long periods, leading to regulatory and clinical uncertainty. Furthermore, the company is navigating a complex legal landscape regarding its patents and is involved in litigation with ToolGen that could impact its future operations.

Valuation comparison

AbbVie offers a more traditional valuation based on its massive cash flow, while CRISPR Therapeutics appears expensive on a sales basis.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Investors use the Forward P/E to compare the stock price to future earnings estimates, while the P/S ratio compares the company value to its annual revenue.

Which stock would I buy in 2026?

I'd go with AbbVie. Its immunology franchise is operating at a level that is difficult to find anywhere else in pharma right now. Skyrizi and Rinvoq are each growing at a pace that keeps pushing management to raise its full-year outlook and the period of painful revenue loss from Humira losing its patent protection is mostly over. The neuroscience portfolio is adding a second major growth engine to an already profitable business, and a growing dividend makes the wait more comfortable.

CRISPR Therapeutics, to its credit, is doing something that very few biotech companies have ever managed. Its Casgevy is an approved, commercially successful gene-editing therapy. Revenue is accelerating, and a recent FDA approval for children as young as two dramatically expanded the eligible patient population.

But CRISPR is still losing a substantial amount of money every quarter, and the entire investment case depends on continued execution over many years. For a long-term investor who wants biotech exposure without betting everything on clinical outcomes, AbbVie is the more comfortable place to put your money.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool recommends CRISPR Therapeutics and McKesson. The Motley Fool has a disclosure policy.